Abstract:Glioblastoma multiforme (GBM) is a heterogeneous malignant brain tumor, the pathological incidence of which induces the accumulation of tumor-infiltrating lymphocytes (TILs). As a tumor suppressor gene, LRRC4 is absent in GBM cells. Here, we report that the recovery of LRRC4 in GBM cells inhibited the infiltration of tumor-infiltrating regulatory T cells (Ti-Treg), promoted the expansion of tumor-infiltrating effector T (Ti-Teff) cells and CD4+CCR4+ T cells, and enhanced the chemotaxis of CD4+CCR4+ T cells in the GBM immune microenvironment. LRRC4 was not transferred into TILs from GBM cells through exosomes but mainly exerted its inhibiting function on Ti-Treg cell expansion by directly promoting cytokine secretion. GBM cell-derived exosomes (cytokine-free and programmed cell death 1 containing) also contributed to the modulation of LRRC4 on Ti-Treg, Ti-Teff, and CD4+CCR4+ T cells. In GBM cells, LRRC4 directly bound to phosphoinositide-dependent protein kinase 1 (PDPK1), phosphorylated IKKβser181, facilitated NF-κB activation, and promoted the secretion of interleukin-6 (IL-6), CCL2, and interferon gamma. In addition, HSP90 was required to maintain the interaction between LRRC4 and PDPK1. However, the inhibition of Ti-Treg cell expansion and promotion of CD4+CCR4+ T cell chemotaxis by LRRC4 could be blocked by anti-IL-6 antibody or anti-CCL2 antibody, respectively. miR-101 is a suppressor gene in GBM. Our previous studies have shown that EZH2, EED, and DNMT3A are direct targets of miR-101. Here, we showed that miR-101 reversed the hypermethylation of the LRRC4 promoter and induced the re-expression of LRRC4 in GBM cells by directly targeting EZH2, EED, and DNMT3A. Our results reveal a novel mechanism underlying GBM microenvironment and provide a new therapeutic strategy using re-expression of LRRC4 in GBM cells to create a permissive intratumoral environment.

Promoter Hypermethylation-mediated Inactivation of LRRC4 in Gliomas

LRRC4, a Putative Tumor Suppressor Gene, Requires a Functional Leucine-Rich Repeat Cassette Domain to Inhibit Proliferation of Glioma Cells in Vitro by Modulating the Extracellular Signal-Regulated Kinase/protein Kinase B/nuclear Factor-Kappab Pathway.

Progress in LRRC4, a Novel Brain-specific Gene/Glioma Suppressive Gene

LRRC4 inhibits glioma cell growth and invasion through a miR-185-dependent pathway.

Study of a novel brain relatively specific gene LRRC4 involved in glioma tumorigenesis suppression using the Tet-on system.

LRRC4 inhibits the proliferation of human glioma cells by modulating the expression of STMN1 and microtubule polymerization.

LRRC4 Inhibits Human Glioblastoma Cells Proliferation, Invasion, and Prommp‐2 Activation by Reducing SDF‐1α/CXCR4‐mediated ERK1/2 and Akt Signaling Pathways

Function of a Novel Brain-Specific Gene LRRC4

LRRC4 inhibits glioblastoma cell proliferation, migration, and angiogenesis by downregulating pleiotropic cytokine expression and responses.

Novel Therapy for Glioblastoma Multiforme by Restoring LRRC4 in Tumor Cells: LRRC4 Inhibits Tumor-Infitrating Regulatory T Cells by Cytokine and Programmed Cell Death 1-Containing Exosomes

Expression and Functional Characterization of LRRC4, a Novel Brain‐specific Member of the LRR Superfamily

Function and mechanism of tumor suppressor gene LRRC4/NGL-2

Expression Absence of LRRC4 Gene in Glioblastoma Cell Lines

Disturbing Mir-182 and -381 Inhibits BRD7 Transcription and Glioma Growth by Directly Targeting LRRC4.

LRRC4 Controls in Vitro Invasion of Glioblastoma Cells Through Inhibiting RPTP-zeta Expression.

Interaction of Hsa-Mir-381 and Glioma Suppressor LRRC4 is Involved in Glioma Growth

Expression of LRRC4 Has the Potential to Decrease the Growth Rate and Tumorigenesis of Glioblastoma Cell Line U251.

The D Domain of LRRC4 anchors ERK1/2 in the cytoplasm and competitively inhibits MEK/ERK activation in glioma cells

Suppression of Growth and Invasion Phenotypes in Glioblastoma U251 Cells by LRR Domain of LRRC4

Blockage of U251 Cells in G0/G1 Through MAPK Signaling Pathway by LRRC4

Hypermethylation of the RASSF1A gene in gliomas.